{"doi":"10.1111/apt.18415","title":"Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk","abstract":"BACKGROUND: Hepatic steatosis (HS) and 10-year atherosclerotic cardiovascular disease (ASCVD) risk ≥ 7.5% are associated with increased risk for cardiovascular events. AIM: To assess underlying coronary artery disease (CAD) and major adverse cardiovascular event (MACE) among those with and without HS at different ASCVD risk. METHODS: We evaluated stable chest pain patients receiving coronary computed tomography (CT) in the PROMISE trial. HS and CAD endpoints were defined on coronary CT. MACE was defined as unstable angina, non-fatal myocardial infarction, and all-cause death. Multivariable Cox regression, adjusting for CAD characteristics, assessed the association of HS with MACE for ASCVD < 7.5%. RESULTS: One thousand two hundred and four of 3702 (32.5%) patients were at ASCVD < 7.5% and 20.3% (244/1204) of them had HS. Individuals with HS were younger (54.3 ± 5.2 vs. 55.8 ± 5.2; p < 0.001), more often males (40.2% [98/244] vs. 27.1% [260/960]; p < 0.001), had more risk factors/person (2.06 ± 0.89 vs. 1.93 ± 0.91; p = 0.047). CAD characteristics were similar between HS vs. non-HS patients at ASCVD < 7.5% and ASCVD ≥ 7.5% (all p > 0.05). Patients with HS had greater MACE rate compared to non-HS patients (ASCVD < 7.5%: 3.75%[9/244] vs. 1.5% [14/960]; p = 0.027 and ASCVD ≥ 7.5%: 4.7% [33/696] vs. 3.1% [56/1802]; p = 0.043). In patients without HS, MACE rate was higher in the ASCVD ≥ 7.5% vs. < 7.5% (3.1% [56/1802] vs. 1.5% [14/960]; p = 0.011). In patients with HS, MACE rates were not significantly different between ASCVD ≥ 7.5% vs. < 7.5% (4.7% [33/696] vs. 3.7% [9/244]; p = 0.484). In ASCVD < 7.5%, HS predicted MACE (aHR:2.34, 95%CI:1.01-5.43; p = 0.048), independent of CAD characteristics. CONCLUSIONS: Individuals with HS at ASCVD < 7.5% risk had similar CAD characteristics as patients without HS at < 7.5% ASCVD risk, yet experienced comparable MACE rates as those at ASCVD ≥ 7.5%.","journal":"Alimentary Pharmacology & Therapeutics","year":2024,"id":478061,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":2,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9318,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":282480,"name":"Thomas Mayrhofer","orcid":"0000-0001-6287-5185","position":1,"is_corresponding":false},{"id":282486,"name":"Borek Foldyna","orcid":"0000-0002-2466-4827","position":2,"is_corresponding":false},{"id":282485,"name":"Michael T. Lu","orcid":"0000-0003-4696-9610","position":3,"is_corresponding":false},{"id":282479,"name":"Nandini M. Meyersohn","orcid":"0000-0001-9826-1097","position":4,"is_corresponding":false},{"id":235806,"name":"Udo Hoffmann","orcid":"0000-0001-5514-769X","position":5,"is_corresponding":false},{"id":1316942,"name":"Oluwafemi Balogon","orcid":null,"position":6,"is_corresponding":false},{"id":271439,"name":"Neha J. Pagidipati","orcid":"0000-0002-5004-8868","position":7,"is_corresponding":false},{"id":33014,"name":"Svati H. Shah","orcid":"0000-0002-3495-2830","position":8,"is_corresponding":false},{"id":282488,"name":"Pamela S. Douglas","orcid":"0000-0001-9876-4049","position":9,"is_corresponding":false},{"id":282489,"name":"Maros Ferencik","orcid":"0000-0001-5872-2223","position":10,"is_corresponding":false},{"id":254443,"name":"Kathleen E. Corey","orcid":"0000-0003-2882-7264","position":11,"is_corresponding":false},{"id":322819,"name":"Júlia Karády","orcid":"0000-0002-6640-6260","position":0,"is_corresponding":true}],"reference_count":37,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T02:06:42.155024Z","pmid":"39610294","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}